Skip to content

Pericapsular Nerve Group and Lumbar Erector Spinae Plane Blocks for Geriatrics Undergoing Total Hip Arthroplasty

Combination of Pericapsular Nerve Group and Lumbar Erector Spinae Plane Blocks for Geriatrics Undergoing Total Hip Arthroplasty Under General Anesthesia: A Randomized Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06904703
Enrollment
120
Registered
2025-04-01
Start date
2024-12-01
Completion date
2026-11-01
Last updated
2025-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pericapsular Nerve, Lumbar Erector Spinae Plane Blocks, Geriatrics, Total Hip Arthroplasty, General Anesthesia

Brief summary

This study will be conducted to evaluate the effect of pericapsular nerve group and erector spinae plane block as adjuvants to general anesthesia in geriatrics undergoing total hip arthroplasty.

Detailed description

Total hip arthroplasty is one of the most common major orthopedic procedures to improve a patient's functional status and quality of life. Total hip arthroplasty is one of the most cost-effective and consistently successful surgeries performed in orthopedics and can be associated with significant postoperative pain. General anesthesia may be considered more versatile and suitable for patients with complex medical histories or those who cannot tolerate spinal anesthesia. However, older patients undergoing hip fracture surgery under general anesthesia may experience a higher risk of postoperative delirium, prolonged sedation, and respiratory complications. Moreover, delayed mobilization is possible, leading to a higher incidence of complications such as deep vein thrombosis and pressure sores. The target nerves of the hip joint arise from the lumbar plexus (L1-L4), the lumbosacral trunk of the sacral plexus (L4-L5), and the sacral spinal nerves (S1-S4) (7). The femoral nerve, obturator nerve, and the accessory obturator nerve supply the anterior capsule of the hip; the sciatic nerve and the nerve to the quadratus femoris mostly supply the articular branches to the posterior capsule of the hip joint The erector spinae plane block is a novel inter-fascial plane block targets the dorsal and ventral rami of the spinal nerves, is a newer regional anesthetic technique that can be used to provide analgesia for a variety of surgical procedures or to manage acute or chronic pain. This block can potentially provide analgesia to the posterior pelvis potentially safer alternative to epidural or paravertebral techniques, areas often involved in hip fracture pain. The pericapsular nerve group block targets the articular branches of the femoral and obturator nerves near the hip joint capsule. By blocking these nerves, the pericapsular nerve group block effectively provides analgesia to the hip joint, particular tissues, and proximal femur.

Interventions

DRUGGeneral anesthesia

Patients will receive general anesthesia.

Patients will receive general anesthesia and erector spinae plane block.

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
75 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged \>75 years. * Both sexes. * American Society of Anesthesiologists (ASA) classification I-III. * Undergoing total hip arthroplasty under general anesthesia.

Exclusion criteria

* Patient refusal. * Body mass index (BMI) \> 30 kg/m2. * Allergy to local anesthesia drugs. * Infection at the site of intervention. * Coagulopathies. * Preexisting advanced diseases of the kidney or liver.

Design outcomes

Primary

MeasureTime frameDescription
Mean sevoflurane MAC to achieve bispectral index (BIS) values (45-55)IntraoperativelySevoflurane will be adjusted to maintain a steady state with a BIS value in the range of 45-55 and will be fixed through the study period

Secondary

MeasureTime frameDescription
Fentanyl consumption.IntraoperativelyAdditional fentanyl bolus dosages of 1 µg/kg IV will be administered if heart rate or mean arterial blood pressure elevated more than 20% of the baseline (after exclusion of other causes than pain).
Arterial blood pressureTill the end of surgery (up to 2 hours)MAP will be recorded pre-induction of anesthesia, post-induction of anesthesia and before performing of block, and every 15 min till the end of surgery. Intraoperative arterial blood pressure will be assessed. Hypotension (decrease in basal mean arterial blood pressure by 20%) will be treated with IV fluid.
Heart rateTill the end of surgery (up to 2 hours)HR will be recorded pre-induction of anesthesia, post-induction of anesthesia and before performing of block, and every 15 min till the end of surgery.
Pain degree24 hours postoperativelyEach patient will be instructed about postoperative pain assessment with the Numerical Rating Scale (NRS). NRS (0 represents no pain while 10 represents the worst pain imaginable).Pain intensity will be measured using a 10-point NRS at rest at 2, 4, 8, 12, 18, and 24 hours postoperatively.
Patient satisfaction24 hours after surgeryDegree of patient satisfaction will be assessed on a 5-point Likert scale patient satisfaction (1, extremely dissatisfied; 2, unsatisfied; 3, neutral; 4, satisfied; 5, extremely satisfied). It will be assessed 24 hours after surgery.
Complications24 hours PostoperativelyComplications such as bradycardia, hypotension, nausea, vomiting, pruritis, respiratory depression will be recorded.
Total postoperative morphine consumption.First 24 hours after surgeryTotal postoperative morphine consumption in the first 24h after surgery will be recorded. Rescue analgesia of morphine will be given as 0.05mg/kg bolus if the Numerical Rating Scale (NRS) \> 3 to be repeated after 30 min if pain persists until the NRS \< 4.

Countries

Egypt

Contacts

Primary ContactMai El Hamada, MSc
drmai7amada93@gmail.com00201285851295

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026